LEADER 02008nas 2200517- 450 001 996326347003316 005 20220413213022.0 011 $a2572-5084 035 $a(DE-599)ZDB2964141-X 035 $a(OCoLC)980871974 035 $a(CKB)4100000002521852 035 $a(CONSER)--2017200252 035 $a(EXLCZ)994100000002521852 100 $a20170403a20179999 --- a 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aJournal of international maritime safety, environmental affairs, and shipping 210 1$aAbingdon, U.K. :$cTaylor & Francis,$d2017- 300 $aRefereed/Peer-reviewed 300 $aProduced by the Korea Institute of Ocean Science and Technology (KIOST) and the Korean Society of Marine Environment and Safety (KOSOMES), with the financial support from Ministry of Oceans and Fisheries of the Republic of Korea (MOF). 517 1 $aSEAS 531 0 $aJ. int. marit. saf. environ. aff. shipp. 606 $aShipping$vPeriodicals 606 $aShipping$xSafety measures$vPeriodicals 606 $aShipping$xEnvironmental aspects$vPeriodicals 606 $aShipping$xSafety measures$2fast$3(OCoLC)fst01116411 606 $aShipping$xEnvironmental aspects$2fast$3(OCoLC)fst01116379 606 $aShipping$2fast$3(OCoLC)fst01116352 608 $aPeriodicals.$2fast 615 0$aShipping 615 0$aShipping$xSafety measures 615 0$aShipping$xEnvironmental aspects 615 7$aShipping$xSafety measures. 615 7$aShipping$xEnvironmental aspects. 615 7$aShipping. 676 $a387.5 712 02$aKorean Society of Marine Environment and Safety, 712 02$aHan'guk Haeyang Kwahak Kisurw?n, 712 02$aKorean Society of Marine Environment and Safety 906 $aJOURNAL 912 $a996326347003316 996 $aJournal of international maritime safety, environmental affairs, and shipping$92182989 997 $aUNISA LEADER 04570oam 2200601 450 001 9910136799803321 005 20230621140038.0 010 $a9782889197767$b(ebook) 035 $a(CKB)3710000000631124 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42645 035 $a(EXLCZ)993710000000631124 100 $a20191103h20152015 fy| 0 101 0 $aeng 135 $aurc|#---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCancer nanotheranostics $ewhat have we learned so far? /$fedited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian 210 $cFrontiers Media SA$d2016 210 1$a[Lausanne, Switzerland] :$cFrontiers Media SA,$d[2015] 210 4$d©2015 215 $a1 online resource (128 pages) $cillustrations (chiefly colour); digital file(s) 225 0 $aFrontiers in Chemistry 225 1 $aFrontiers Research Topics 311 08$aPrint version: Cancer nanotheranostics: what have we learned so far? [Lausanne, Switzerland]: Frontiers Media SA, 2015 288919776X 320 $aIncludes bibliographical references. 330 3 $aAfter a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells... Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem?s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncology; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities. 410 0$aFrontiers research topics. 606 $aCancer$xTreatment 606 $aNanostructured materials$xHealth aspects 610 $aNanoparticles 610 $aGene Therapy 610 $aImmunotherapy 610 $abioimaging 610 $atheranostics 610 $ananomaterials 610 $aDrug delivery 610 $aNanomedicine 610 $aCancer 610 $aPhototherapy 615 0$aCancer$xTreatment. 615 0$aNanostructured materials$xHealth aspects. 676 $a616.99406 700 $aPedro Viana Baptista$4auth$01366189 702 $aConde?$b Joa?o$cPhD, 702 $aBaptista$b Pedro Viana 702 $aFuente$b Jesus M. de la$f1975- 702 $aTian$b Furong$f1971- 801 0$bUkMaJRU 906 $aBOOK 912 $a9910136799803321 996 $aCancer nanotheranostics$93388690 997 $aUNINA